ASTRAZENECA PLC reports

6-K File 001-11960

ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS

Filing date

18 May 2026

Reporting date

18 May 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER

Filing date

14 May 2026

Reporting date

14 May 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

TOTAL VOTING RIGHTS AND ADMISSION OF SHARES

Filing date

01 May 2026

Reporting date

01 May 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER

Filing date

01 May 2026

Reporting date

01 May 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCER

Filing date

01 May 2026

Reporting date

01 May 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

1ST QUARTER RESULTS

Filing date

29 Apr 2026

Reporting date

29 Apr 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

BREZTRI APPROVED IN THE US FOR ASTHMA

Filing date

28 Apr 2026

Reporting date

28 Apr 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

SAPHNELO SELF-ADMINISTRATION APPROVED IN THE US

Filing date

27 Apr 2026

Reporting date

27 Apr 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

DIRECTORATE CHANGE

Filing date

23 Apr 2026

Reporting date

23 Apr 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

I CAN PHIII INTERIM ANALYSIS MET PRIMARY ENDPOINT

Filing date

21 Apr 2026

Reporting date

21 Apr 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

THIRD TOZORAKIMAB POSITIVE PHASE III IN COPD

Filing date

20 Apr 2026

Reporting date

20 Apr 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

RESULT OF AGM

Filing date

09 Apr 2026

Reporting date

09 Apr 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

IMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCER

Filing date

02 Apr 2026

Reporting date

02 Apr 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

TOTAL VOTING RIGHTS AND ADMISSION OF SHARES

Filing date

01 Apr 2026

Reporting date

01 Apr 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

EFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTS

Filing date

31 Mar 2026

Reporting date

31 Mar 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS

Filing date

27 Mar 2026

Reporting date

27 Mar 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

NOTIFICATION OF ADMISSION OF SHARES

Filing date

20 Mar 2026

Reporting date

20 Mar 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCER

Filing date

16 Mar 2026

Reporting date

16 Mar 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

NOTICE OF AGM

Filing date

10 Mar 2026

Reporting date

10 Mar 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

FORM 6-K

Filing date

10 Mar 2026

Reporting date

10 Mar 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date

06 Mar 2026

Reporting date

06 Mar 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date

06 Mar 2026

Reporting date

06 Mar 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date

06 Mar 2026

Reporting date

06 Mar 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

FORM 6-K

Filing date

02 Mar 2026

Reporting date

02 Mar 2026

SEC evidence

Open document Open filing

Next action

Verify source filing

6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date

02 Mar 2026

Reporting date

02 Mar 2026

SEC evidence

Open document Open filing

Next action

Verify source filing